Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Licensing agreement deals decline in rare diseases space, says GlobalData

Licensing agreements are decreasing in the rare disease space in favor of more complex collaborations and partnerships. Indeed, of the strategic alliances formed by the top ten bio/pharma companies (by market cap) in the last year, 17% were in the rare diseases space, according to the GlobalData Pharmaceutical Intelligence Center Deals Database. Madeleine Roche, Associate […]
Read more

Monjuvi approval in relapsed/refractory DLBCL could lead home run for Morphosys/Incyte against big players, says GlobalData

Following the FDA’s recently granted accelerated approval for Morphosys and Incyte’s CD19 targeting antibody Monjuvi (tafasitamab), Morphosys and Incyte partnership now pushes forward to compete with Roche’s well-established diffuse large B-cell lymphoma (DLBCL) franchise as the go-to option in the second line and beyond treatment setting. Monjuvi could represent a safer, more effective, and affordable […]
Read more

ACTIV initiative could help speed up COVID-19 therapeutics and vaccines by making research more efficient

With the rapid proliferation of clinical trials addressing COVID-19, the US National Institutes of Health (NIH) launched the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, which could help speed up the delivery of therapeutics, says GlobalData, a leading data and analytics company. The ACTIV initiative is a public-private partnership effort to address the COVID-19 […]
Read more
,

17 of 20 top pharmaceutical companies be revenue reported YoY growth in 2019, says GlobalData

As another great year for the innovation bio/pharma industry, 2019 saw 17 of the top 20 mega cap players reporting YoY revenue growth, according to GlobalData, a leading data and analytics company. Madeleine Roche, Associate Pharma Analyst at GlobalData commented, “One winner was Takeda, which saw more than 50% YoY revenue growth. The company’s significant […]
Read more

SC Remsima will need cost-effective pricing to further erode the shares of Remicade, says GlobalData

Following the news that the first subcutaneous (SC) formulation of Celltrion’s Remsima (infliximab-dyyb/CT-P13) was granted marketing authorization by the European Commission (EC) for all indications in adults for which the intravenous formulation is also approved*, GlobalData notes that, in order for Celltrion to further erode market share of its rival Remicade – and other anti-TNF […]
Read more

Remdesivir and favipiravir price regulation required to safeguard patients’ interest in India, says GlobalData

Regulatory bodies such as the National Pharmaceutical Pricing Authority (NPPA) and the Drug Controller General of India (DCGI) are keeping a close eye on remdesivir and favipiravir amid the COVID-19 pandemic to safeguard patients’ interest around pricing, says GlobalData, a leading data analytics and research company. The Indian Council of Medical Research (ICMR) has recently […]
Read more

Evidence that COVID-19 in pregnant women could mimic preeclampsia can help with patient management but more data needed to prove link, says GlobalData

Following the news that there is evidence that COVID-19 infection in pregnant women can exhibit signs that mimic a severe form of preeclampsia such as hemolysis, elevated liver enzymes and low platelet count (HELLP), GlobalData notes that while this evidence can be taken into consideration during the evaluation of high-risk patients presenting signs of preeclampsia […]
Read more

IMU-838 could be alternative treatment option for RRMS patients who are ineligible with mAbs, says GlobalData

Following the publication of positive top-line data from the Phase II EMPhASIS trial of IMU-838 (vidofludimus calcium) in patients with Relapsing-Remitting Multiple Sclerosis (RRMS) by Immunic; Alessio Brunello, Managing Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “Patients who are ineligible for treatments with monoclonal antibodies (mAbs) might benefit from […]
Read more

Novaliq’s CyclASol could become preferred cyclosporine formulation if pivotal trial succeeds

Novaliq recently announced its agreement with the US Food and Drug Administration (FDA) regarding the second registrational trial ESSENCE-2 for its late-stage therapy, CyclASol, for dry eye syndrome (DES). This is a positive development for the DES market, particularly due to its favorable tolerability profile, according to GlobalData, a leading data and analytics company. ESSENCE-2 […]
Read more

Biocon and Voluntis deal aims to personalize treatment for type 2 diabetic patients on insulin, says GlobalData

Biocon Sdn. Bhd., Malaysia, a subsidiary of Biocon Biologics, and digital therapeutics company Voluntis have recently announced a global collaboration agreement to develop and distribute FDA-cleared and CE-marked digital therapeutic product ‘Insulia’ for type 2 diabetes (T2D) patients across several markets. The deal will make Insulia available to a large number of Biocon’s biosimilar insulin […]
Read more

AstraZeneca’s Breztri will overcome late entry to COPD market

Following the news that the Food and Drug Administration granted AstraZeneca’s Breztri approval in the US for chronic obstructive pulmonary disease (COPD); Angad Lotay, MPharm, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view: “Despite its late market entry, GlobalData believes AstraZeneca will still catapult ahead, not only in COPD patients, but eventually […]
Read more

AstraZeneca’s, Johnson & Johnson/AbbVie’s and BeiGene’s oncology therapies repurposed for COVID-19 have class effect undermined by dissimilarities, says GlobalData

Although AstraZeneca, Johnson & Johnson/AbbVie and BeiGene all have oncology therapies, known as BTK inhibitors, repurposed for COVID-19 treatment, there are still important nuanced differences, according to reporting by Ayisha Sharma, Pharma Writer for the Investigative News team at GlobalData, a leading data and analytics company. Sharma says: “In particular, AstraZeneca’s Calquence could have a […]
Read more

Number of US COVID-19 clinical trials surpasses China, says GlobalData

There are more than 1,039 COVID-19 potential drugs and 2,737 clinical trials for COVID-19 globally, with more than 430 of these being run in the US, despite the pandemic causing disruptions in clinical trials, says GlobalData, a leading data and analytics company. Johanna Swanson, Product Manager at GlobalData, comments: “The US has the highest number […]
Read more
1 … 84 85 86 87 88 … 110